# reload+after+2024-01-21 07:44:06.493477
address1§900 North Point Parkway
address2§Suite 200
city§Alpharetta
state§GA
zip§30005
country§United States
phone§678 270 3631
fax§678 270 4033
website§https://clearsidebio.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. Clearside Biomedical, Inc. has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
fullTimeEmployees§36
companyOfficers§[{'maxAge': 1, 'name': 'Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.', 'age': 71, 'title': 'President, CEO & Director', 'yearBorn': 1952, 'fiscalYear': 2022, 'totalPay': 816400, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Charles A. Deignan', 'age': 59, 'title': 'Chief Financial Officer', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 536950, 'exercisedValue': 0, 'unexercisedValue': 24545}, {'maxAge': 1, 'name': 'Dr. Thomas A. Ciulla M.B.A., M.D.', 'age': 59, 'title': 'Chief Medical Advisor-Retina', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 597205, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Jenny R. Kobin', 'age': 56, 'title': 'Head of Investor Relations', 'yearBorn': 1967, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Rick  McElheny', 'title': 'Vice President of Corporate Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Rafael V. Andino', 'age': 58, 'title': 'Senior Vice President of Engineering & Manufacturing', 'yearBorn': 1965, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Susan L. Coultas Ph.D.', 'title': 'Chief Clinical Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Leslie B. Zacks', 'age': 54, 'title': 'Secretary', 'yearBorn': 1969, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§2.269
priceToSalesTrailing12Months§37.823578
currency§USD
dateShortInterest§1702598400
forwardEps§-0.58
exchange§NGM
quoteType§EQUITY
shortName§Clearside Biomedical, Inc.
longName§Clearside Biomedical, Inc.
firstTradeDateEpochUtc§1464874200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§ea57bdfa-5d41-3e30-b431-13e72798980d
gmtOffSetMilliseconds§-18000000
targetHighPrice§8.0
targetLowPrice§4.0
targetMeanPrice§5.67
targetMedianPrice§5.5
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§6
quickRatio§5.087
grossMargins§0.74717003
ebitdaMargins§0.0
trailingPegRatio§None
